NVCT
Nuvectis Pharma, Inc.
Next earnings Aug 3, 2026 · consensus $-0.26 EPS
Last earnings +9.2% on 2026-05-05
$24.48
▲ +39.49%$24.48▲ +204.10%
over 1Y
L $5.65EODHDH $24.48
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+39.5%
1W+94.4%
1M+142.4%
3M+207.5%
YTD+187.7%
1Y+204.1%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 11 analysts
Buy
Conservative balance sheet (liabilities/equity 0.72x).
Nuvectis Pharma, Inc. shows limited reported revenue, and -143.6% ROE.
Sources: SEC EDGAR (CIK 0001875558, latest 10-Q filed 2026-05-05) · EODHD · as of 6/25/2026, 4:57:41 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.